Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Shares Issued (2016 - 2025)

Integra Lifesciences Holdings' Shares Issued history spans 17 years, with the latest figure at $957000.0 for Q1 2025.

  • For Q1 2025, Shares Issued fell 85.04% year-over-year to $957000.0; the TTM value through Dec 2025 reached $957000.0, down 85.04%, while the annual FY2025 figure was $957000.0, 85.04% down from the prior year.
  • Shares Issued for Q1 2025 was $957000.0 at Integra Lifesciences Holdings, down from $6.4 million in the prior quarter.
  • Across five years, Shares Issued topped out at $6.4 million in Q1 2024 and bottomed at $225000.0 in Q4 2023.
  • The 5-year median for Shares Issued is $1.2 million (2022), against an average of $1.8 million.
  • The largest annual shift saw Shares Issued skyrocketed 1541.1% in 2022 before it plummeted 94.19% in 2023.
  • A 5-year view of Shares Issued shows it stood at $236000.0 in 2021, then surged by 1541.1% to $3.9 million in 2022, then tumbled by 94.19% to $225000.0 in 2023, then soared by 2743.56% to $6.4 million in 2024, then plummeted by 85.04% to $957000.0 in 2025.
  • Per Business Quant, the three most recent readings for IART's Shares Issued are $957000.0 (Q1 2025), $6.4 million (Q1 2024), and $225000.0 (Q4 2023).